Nearly twenty years after the initial discovery of p53, we are now in an ideal position to exploit our vast knowledge of p53 biology in the creation of novel cancer therapies. Disruption of p53 function through mutation, or other means, occurs very frequently in human cancer. Loss of p53 function has been linked with unfavourable prognosis in a large number of tumour types, as indicated by more aggressive tumours, early metastasis and decreased survival rates. Many different avenues of research have converged upon p53 to highlight this protein as being one of the foremost cellular responders to stress, in particular to DNA damage. Huge advances have been made in understanding the complex role p53 plays in the regulation of apoptosis and cell cycle arrest. This review is not meant to be a comprehensive description of p53 biology, but rather serves to highlight current progress in the development of p53-oriented cancer therapies. These may be categorised into three basic strategies: gene replacement therapy using wild-type p53, restoration of p53 function by other means and, finally, targeting of the p53 dysfunction itself. Rapid progress is expected to be made regarding the identification of conventional pharmaceutical agents which either work in a p53-independent manner or act preferentially in p53 defective cells. Gene replacement therapy with wild-type p53 also holds considerable potential for obtaining clinically relevant results quickly. The other forms of cancer therapies based around p53 are much further behind in the developmental process, but may prove to more efficacious in the long run, especially in terms of specificity. As with many other fields, the innovation of successful p53-oriented cancer therapies is only limited by our understanding of p53 biology and the creative use of such knowledge.
Introduction
A major barrier to the effective treatment of human cancer is the inherent or acquired resistance of certain tumours to both radio-and chemotherapy. DNA appears to be the primary target for most of the currently used cytotoxic anti-tumour agents. The 53kDa protein product of the p53 tumour suppressor gene is known to be one of the key players in the cellular response to DNA damage [1, 2] . In addition to being influenced by genotoxic stress, p53 appears to mediate a more general anti-proliferative response to suboptimal growth conditions. For example, both hypoxia and heat have been demonstrated to activate p53, as does cellular starvation through serum depletion [3] [4] [5] . Thus, p53 is implicated as being in a pivotal position to down-regulate cell growth in response to a variety of intra-and extracellular signals. Perhaps, this may explain why functional inactivation of p53, by mutation or otherwise, occurs at such a high frequency during tumourigenesis [6, 7] .
DNA damage induced activation of p53 can result in either cell cycle arrest or apoptosis [8] . Furthermore, p53 activation may lead to effects on other cellular processes such as DNA replication and repair [1, 9] . In response to DNA damage, wild-type p53 protein accumulates within the nucleus and can activate or repress transcription of various target genes. Alternatively, the biological effects of p53 may be mediated by interactions between p53 and specific protein partners. Although the exact nature of the signal pathway leading from DNA damage to p53 activation is not fully understood, it is clear that the decision between p53-mediated cell cycle arrest or apoptosis is influenced by both cell type and environment [8] . Both the activity and the behaviour of the p53-dependent DNA damage response pathway are significant factors in determining the nature of tumour development and the response to therapeutic intervention.
The main purpose of this review is to outline the recent advances in the development of p53-oriented cancer therapies, which provide not only a further insight into the biological implications of the p53 pathway but may also deliver novel therapeutic approaches. More comprehensive reviews focusing on p53 biology can be found elsewhere [1, 10] .
Cell-cycle arrest and apoptosis
The role of p53 in regulating the Gj/S cell cycle checkpoint in response to DNA damage is well documented [11] . Presently, there are two models to explain the nature and purpose of the p53-dependent-Gi arrest pathway. In 140 one model, p53 mediates a transient d arrest to allow time for DNA repair prior to entry into S phase [12] . However, an alternative model has been proposed in which this growth arrest is permanent and, hence, permits the elimination of cells containing unrepaired DNA damage from the reproductively viable population [13] . It is self-evident that the response of a malignancy to many currently used anti-tumour agents will depend upon both the status of p53 and the exact format of the growth arrest pathway, i.e., reversible or irreversible.
A major effector of the p53-mediated G\ arrest is thought to be the protein product of the CIP1/WAF1 gene [14] . The CIP1 gene is a transcriptional target for p53 and contains two p53-binding sites. The 21kDa encoded protein forms part of a quaternary complex found in normal cells along with cyclin, cyclin-dependent kinase (CDK) and PCNA [15] . Induction of CIP1 expression by activated p53 inhibits the function of those cyclin/CDK complexes which are predominantly found during G] phase of the cell cycle [16] . Such inhibition results in the accumulation of hypophosphorylated Rb protein which prevents the E2F protein, through direct sequestration, from being able to promote Gi to S phase transition [17] . The importance of CIP1 in regulating cell cycle progression was underlined by the observation that CIP1 null cells display a defective G\ arrest in response to radiation treatment [18] . It must be noted that expression ofCIPl is also regulated by p53-independent mechanisms [19] . As a final point, p53 may have additional roles in the control of the G 2 arrest pathway [20] [21] [22] and the mitotic spindle checkpoint [23] .
Substantial evidence has accumulated to suggest that p53 is also a positive regulator of programmed cell death [24] . Cells obtained from p53 null mice have been shown to be resistant to the induction of apoptosis by radiation and chemotherapy [25] [26] [27] . Indeed, the effectiveness of a variety of cancer therapies in vivo is dependent on the ability to induce a p53-mediated apoptotic response [28] . The Bax gene is a transcriptional target of p53 and encodes a protein with homology to the survival factor encoded by the bcl-2 oncogene [29] . In addition, expression of bcl-2 is repressed by p53 [30] . Both bcl-2 and Bax proteins can heterodimerise and the relative levels of these proteins (and other family members) are critical to the regulation of the apoptotic process [31] . However, it is clear that apoptosis can also occur by pathways independent of p53 [32] . Chemotherapeutic agents such as cisplatin and paclitaxel can cause induction of Bax and Bak, pro-apoptotic bcl-2 family members, by p53-dependent and -independent mechanisms [33] . Some studies have indicated that p53 may also have a transcriptional regulation-independent function in apoptosis [34, 35] . Indeed, evidence has suggested that the binding of p53 to the transcription-repair complex TFIIH may, apart from affecting DNA repair efficiency, induce apoptosis [36] . A host of other genes which are controlled at the level of transcription by p53 have been identified, along with a large number of proteins which specifically interact with wild-type p53 [1] . The role of these new players in p53-dependent cell cycle arrest and apoptosis, and other activities, are in the process of being characterised.
Nature ofp53 dysfunction in human cancer
As mentioned, the p53 gene is frequently mutated in a variety of human cancers [6, 7] . The most prevalent genetic abnormalities of the p53 gene are missense mutations which give rise to full-length protein products containing single amino acid substitutions within the sequence-specific DNA binding domain [6] . Mutation of p53 may affect its ability to suppress tumourigenesis through one, or a combination, of the following modes: (a) loss of wild-type p53 function (b) dominant negative .effect of mutant p53 over wild-type p53 (c) gain of additional oncogenic properties that are not dependent upon inhibition of wild-type p53 [1] . Some common tumourderived p53 mutants display distinct oncogenic properties, the classic example being co-operation with activated ras in the transformation of rat embyro fibroblasts [37] . The currently favoured explanation of this phenomenon is that the wild-type p53 pathway is overwhelmed by a dominant negative effect which is due to the formation of dysfunctional hetero-tetramers between mutant and wild-type p53 proteins [38] . On the other hand, the concept that p53 mutants can acquire additional oncogenic properties that are not dependent upon inhibition of wild-type p53 is still controversial [39] . A variety of novel mutant p53-specific functions have been described including activation of transcription from several viral and cellular promoters, which are otherwise insensitive to or repressed by wild-type p53, and modified binding specificity for various protein partners [40] [41] [42] [43] .
Mutation of the p53 gene is not the only mechanism by which the p53 pathway can be inactivated. A large number of cellular and viral proteins have been shown to cause p53 dysfunction through either sequestration or degradation of the wild-type p53 protein [7] . A prime example is the protein product of the MDM2 cellular proto-oncogene which is overexpressed in a variety of human tumours and can inhibit p53 function through direct binding and shielding of the transcriptional activation domain of p53 [44] [45] [46] . More recent evidence has indicated that the Mdm2 protein may also target wildtype p53 protein for ubiquitin-dependent degradation [47] . Retention of wild-type p53 protein in the cytoplasm has been observed in inflammatory breast carcinomas and undifferentiated neuroblastomas [48] . It is likely that one or more p53-interacting cytoplasmic proteins are responsible for preventing p53 from reaching its nuclear site of action in these cells. Viral proteins which have the ability to bind to and disrupt wild-type p53 function include among others the human papilloma virus (HPV) E6 and the hepatitis B virus X proteins [49, 50] . For example, the oncogenic HPV E6 protein is believed to inhibit p53 function either by blocking the sequence-specific DNA binding activity of p53 or by labelling newly synthesised p53 as a target for ubiquitinmediated degradation [51, 52] . Inactivation of the p53 pathway may also result from defects in the upstream signalling pathway which normally leads to activation of p53 in response to stress. It is known that the p53 protein can undergo extensive posttranslational modification (53) . Evidence is accruing to indicate that alterations in the pattern of phosphorylation and acetylation occur within p53 subsequent to stress induction [54, 55] , with these steps perhaps being important for p53 activation. However, the signalling intermediates leading from stress to such modifications within p53 are still unclear. Some potential candidates include protein kinases such as the ATM gene product and the histone acetyltransferases,/7i00 and PCAF. As a final point, it is readily conceivable that in certain tumours other, as yet unknown, defect(s) may be present in critical downstream components of the p53 pathway, thus switching p53 activation into an impotent event.
Diagnosis, prognosis and response to anti-tumour agents
Given the high prevalence of p53 inactivation experienced in human cancer, it is clear that p53 status has considerable potential as a clinical marker in malignancy [56, 57] . Depending upon the tissue type examined, p53 mutations can occur at different stages in neoplastic progression. If rational therapeutic strategies targeting mutantp53 are to be successful, then characterisation of p53 status of the tumours to be treated will be essential.
The presence of p53 mutation has been associated with unfavourable prognosis in a variety of tumour types, for example in cancers of the lung, colon and breast [56, 57] . In particular, p53 dysfunction correlates with more aggressive tumours, early metastasis and decreased survival rates. The majority of studies within the literature have indicated that loss of p53 function confers increased resistance to many anti-tumour agents [28, 58] . A similar association between p53 dysfunction and enhanced resistance has been observed in a number of studies involving human cancer patients [58, 59] . As an example, a large study incorporating 316 consecutively presented breast cancers indicated a strong relationship between p53 mutation and reduced effectiveness of adjuvant systemic therapy along with radiation [60] . However, experimental evidence also exists indicating that inactivation of p53 can have either no apparent effect on therapeutic outcome or may, in some cases, enhance sensitivity to DNA damaging agents [61, 62] .
The above variation in the effect of p53 status upon therapeutic responsiveness may be representative of underlying differences in the nature of the p53-mediated DNA damage response pathway, i.e., due to cell type and environmental context. Critical to this idea are the apparently ambiguous roles played by p53 in the promotion of, on the one side, reversible growth arrest and, on the other, apoptosis and irreversible growth arrest. This is further complicated by the potential of dead cells undergoing irreversible cell cycle arrest, but not undergoing apoptosis, supporting growth of viable tumour cells in vivo. Thus cells which have lost a Gl arrest due to loss of the cell cycle kinase inhibitor CIP1 (p21) show no difference compared to CIP1 proficient cells in sensitivity to ionising radiation in vitro, but do show differences in radiation sensitivity if the cells are grown as xenografts in vivo [63] .
p53-Oriented therapies: From the bench to the clinic Although p53 biology is clearly complex, many investigators are attempting to utilise current knowledge in the creation of cancer therapies based around p53. These may be categorised into three basic strategies: gene replacement therapy using wild-type p53, restoration of p53 function in a manner which is independent of wildtype p53 gene transfer and, finally, targeting of the p53 dysfunction itself (Table 1) . Only a handful of clinical trials examining the potential of p53-oriented therapies are currently underway, with fewer still having been fully completed. Therefore, the majority of studies validating these approaches are still at the pre-clinical stage and have to be interpreted with care. Determination of the exact type of p53 dysfunction present within the tumour undergoing treatment, along with analysis of other relevant genetic abnormalities, will be of primary importance when assessing which mode of intervention is to be used. Perhaps the most successful results will be experienced in those studies which seek to determine if combination of p53-oriented therapies with conventional anti-tumour agents is more effective than either treatment alone.
Gene replacement therapy using wild-type p53
It is now clear that both cell transformation and neoplastic cell growth can be suppressed by re-introduction of the wild-type p53 gene into tumour cells with lost or dysfunctional p53 -even in cells which contain multiple genetic abnormalities [64] [65] [66] . The effectiveness of many conventional therapeutic agents is determined, at least in part, by a p53-dependent mechanism. Therefore, restoration of p53 function might also lead to sensitisation of resistant tumour cells to such agents [58, 59] . In recent years, considerable effort has been made to design clinically effective gene replacement strategies using wildtype p53 for the treatment of human cancer [67] . The primary requirement of such cancer gene therapies is the necessity for highly efficient delivery of the wild-typep53 gene into tumour cells in vivo. There also must be sufficient expression of functional p53 protein to mediate tumour suppression either through a direct mechanism involving cell death/growth arrest or by increasing sensitivity to conventional anti-tumour agents. Other critical success factors include a low level of toxicity towards normal cells and the absence of a detrimental host immune response against the gene delivery system used. The mechanisms of gene delivery, which are currently being investigated for potential use in />JJ-based gene replacement therapy, can be subdivided into two broad categories: viral or non-viral. A comprehensive discussion on both the merits and disadvantages of the vectors presently used in clinical trials involving cancer gene therapy may be found within [68] .
Viral delivery systems
Retroviruses are attractive candidates for use in cancer gene therapy applications in that these viral vectors integrate stably into the genome of infected cells and require cell division for transduction. Despite the efficiency of transduction being relatively low, retroviral vectors are used in the majority of approved gene transfer clinical protocols [68] . In several revealing studies, Jack Roth and his colleagues demonstrated that retrovirusmediated gene transfer of the wild-type p53 gene into both human lung tumour cell line and xenograft models could lead to inhibition of tumour cell growth [69] [70] [71] . The adverse effect on cell growth was limited to tumour cells which contained a defective p53 pathway (they were either null for p53 or had inactivating missense mutations within the p53 gene). Furthermore, the growth rate of non-infected lung cancer cells was shown in mixing experiments to be reduced by cells which had been transduced with the wild-type p53 gene, therefore suggesting the possibility of a 'bystander' effect [69] . The exact molecular basis of this 'bystander' effect is unclear at present, although it may involve: (a) exudation of cell death signal molecules from transduced, dying cells to neighbouring untransduced cells (b) phagocytotic uptake of apoptotic vesicles by untransduced cells which in turn induce apoptosis (c) activation of an immune response against the tumour [68] (see also later section on angiogenesis). A direct implication of such a 'bystander' killing process is that less than 100% of cells within a tumour need to be transduced with the wild-type p53 gene for a complete therapeutic response to occur, with perhaps only a small proportion ( < 10%) of transduced cells being ultimately necessary.
Encouraged by the results from these pre-clinical studies, a phase I trial was undertaken to determine the toxicity of retrovirus-mediated delivery of the wild-type p53 gene into human lung tumour cells [72] . A group of nine patients having evidence of primary non-small-cell lung cancer were injected intratumourally with a retrovirus expressing p53. Patients were only included in the study if analysis of tumour biopsies showed the presence of a p53 mutation. Gene transfer was demonstrated in all of the patients who fully completed the specified treatment protocol, as determined by either PCR or in situ hybridisation techniques. Additionally, increased apoptosis, as indicated by TUNEL analysis, was observed in post-treatment biopsies when compared to pre-treatment samples. Regression of the injected tumour was noted in three patients, while in another three patients tumour growth appeared to have stabilised. No significant vector-related toxic side effects were reported during a five month observation period following treatment, although some complications were experienced, such as transient fever and respiratory distress, which were attributed by the investigators to the particular administration procedures used.
Although other investigators use retroviral vectors, the viral vector of current favour in gene replacement therapy using wild-type p53 is based on the doublestranded DNA adenovirus serotype 5. Adenoviruses are capable of high efficiency transduction of a wide range of cell types and are not limited to actively proliferating cells [68] . As adenoviruses do not integrate into the genome of the host cell, they are transient expression vectors and, therefore, do not carry the same risk of causing insertional mutagenesis as in retorviral transduction. This might also be considered a disadvantage if sustained expression of p53 is required to mediate tumour suppression through a reversible growth arrest mechanism, but not in the case of those cell types where p53 activation leads to either apoptosis or irreversible growth arrest. One particular point of concern frequently expressed over the utilisation of adenoviral vectors for gene therapy is the possible induction of an adverse immune response within the treated patient, which in turn may compromise repeat administration of therapeutic virus.
Despite this, many studies have indicated promising results with respect to tumour cell growth suppression when using adenovirus-mediated transfer of the wild-type p53 gene, both in pre-clinical models and preliminary trials with cancer patients [67] . In general, gene delivery by/?55-adenovirus caused specific inhibition of tumour cell growth only in those cells which contained mutated p53 or were/>55 null. Both normal cells and tumour cells retaining p53 function were not adversely affected to any significant degree by the expression of exogenous wildtypep53, at doses of/?55-adenovirus required to dramatically inhibit the growth ofp53 deficient cells. However, certain tumour cells exhibited a high level of resistance to transduction by p53-adenovirus, in which case alternative delivery systems can be considered [73, 74] . A noteworthy trend may be seen in the growing proportion of pre-clinical studies which are combining p53 -adenovirus treatment with other, more traditional, cancer therapies, for example radiation and cisplatin [67] . Most of these studies indicated that combination therapy was more effective than either treatment alone. Of particular interest is the potential use of other adenovirally transferred genes in combination with p53-adenovirus treatment, such as CIP1 or pl6INK4/CDKN2, which can cooperate with/>55 in mediating tumour regression [75, 76] .
Other viral vectors may overtake both the retrovirus and adenovirus as delivery vehicles for gene replacement therapy using wild-type p53 in certain clinical situations, for example the utilisation of herpes simplex virus (HSV) for gene therapy of brain tumours [77, 78] . A recent innovative study indicated that the HSV protein VP22 alone was sufficient to mediate intercellular delivery of functional p53 protein, formulated as a fusion protein with the virion protein [79] .
Non-viral delivery systems
Several different non-viral strategies are presently being examined for their ability to deliver wild-type p53 expression plasmids in vivo and to mediate effective antitumour responses -direct DNA injection and cationic lipid-mediated gene transfer are primary examples. Although generally less efficient than the viral systems described above in actual delivery of the transgene to target cells, advantages of such non-viral approaches include an apparent tolerance by the immune system and reduced concerns over safety issues such as containment.
Following direct injection in vivo of 'naked' (i.e., without viral or synthetic vector) plasmid DNA, cells can spontaneously take up the foreign DNA and permit expression of the enclosed transgene [80, 81] . A phase I trial was initiated in July 1994 to determine the effect of percutaneous intratumoural injection of a 'naked' wildtype p53 expression plasmid into patients having either primary or secondary liver tumours [82] [83] [84] . Initial results showed no objective tumour responses after injection of the wild-type p53 expression plasmid into patients which had evidence of colorectal liver metastases. However, some degree of success was noted in those patients who were suffering from primary hepatocellular carcinoma (HPQ. At present, four out of the eight HPC patients injected with the wild-type p53 expression plasmid have demonstrated significant reductions in both the levels of a-fetoprotein, a serum marker for malignancy, and in tumour volume (> 50%) as measured by computer tomographic scans. However, this study is lacking in two critically important aspects. Firstly, as the pre-treatment tumour biopsies were not screened for the presence of p53 alterations, no conclusions could be drawn as to why some tumours responded and others did not. Secondly, the investigators were unable to determine whether the exogenously introduced wild-typep53 was expressed within the injected tumours. While the DNA injection procedure did not directly cause mortality or morbidity, the following complications were observed: transient fever, hypotension and hypertension.
A more promising non-viral delivery approach stems from the utilisation of cationic liposomes, complexed with plasmid DNA carrying the transgene of interest, which can be efficiently endocytosed by mammalian cells [85] . The main advantages of lipid-mediated gene transfer are that the process is relatively non-toxic and, perhaps, non-immunogenic. Hence, liposomes may permit multiple administrations of the wild-type p53 gene, which is likely to be necessary for the successful treatment of metastatic tumours. In a similar fashion to adenoviruses, liposomes are transient expression vectors. As yet, no clinical trials are employing liposomes to mediate transfer of the wild-type p53 gene into cancer patients [67] . However, a number of pre-clinical studies have indicated that this means of gene delivery can be highly effective in terms of tumour suppression [73, 86, 87] . Direct injection of liposome-/755 complexes into human breast tumours grown as implants within nude mice caused not only regression of the primary tumour but also prevention of both tumour relapse and metastasis [73] . Further investigation suggested that this antitumour effect was mediated, at least in part, by inhibition of angiogenesis [87] . No evidence of non-specific toxicity within the mouse was seen with dosages of liposome-/>55 complex that were sufficient to markedly inhibit growth of the breast tumours [87] . The addition of transferrin to liposome-/755 complexes dramatically increased the transfection efficiency of this vector system and may provide some degree of selective targeting, as transferrin receptors have been found to be elevated in various types of cancer cells [88] . It is of interest to note that transferrin-liposome-mediated transfer of the wildtype p53 gene into a radioresistant squamous cell carcinoma cell line resulted in sensitisation of these cells to ionising radiation treatment [88] . One potential bonus with liposome-based p53 delivery is the ease of regional administration through the airways to sites within the lung bearing cancerous lesions [89] .
p53 and angiogenesis -another explanation of the 'bystander' effect
As indicated earlier, wild-type p53 appears to have a negative effect on the angiogenic process, most likely mediated through transcriptional repression of angiogenic factors such as thrombospondin-1 and VEGF [90, 91] . For many tumour types, once a critical mass is reached, increased tumour growth becomes limited by the existing blood supply. Angiogenic factors serve to increase vascularisation. If wild-type p53 suppresses angiogenesis, this may provide another explanation of the previously-mentioned 'bystander' effect. Several other recent reports examining wild-type p53 gene replacement therapy have also indicated a potential added benefit in terms of reduced angiogenesis upon treatment [92] [93] [94] . Certain forms of mutant p53 have also been suggested to regulate VEGF expression but in a positive fashion [95] . Thus, p53-oriented therapeutic strategies which aim to inhibit angiogenesis could be designed to tackle this phenomenon, perhaps by targeting the angiogenesispromotingp53 mutation itself (see later sections).
Other strategies to restorep53 function
Gene replacement therapy using wild-typep53 is not the only way to restore function to a defective p53 pathway. One intensively studied strategy is the re-conversion of mutant p53 into a form which is capable of mediating tumour growth suppression. It is hoped that the identification of intragenic suppressor mutations may provide insight into the type of molecules needed to reverse the effect of mutation within the p53 gene [96, 97] . Examples from both 'contact' and 'structural' p53 mutant classes have been coaxed into exhibiting, previously defunct, wild-type p53 functional characteristics [98, 99] . Some p53 mutants have temperature-sensitive phenotypes, showing mutant characteristics at 37 °C, but wild type function at 32 °C [24, 100] . At the lower permissive temperature, these mutants display wild-type p53 function. As the temperature rises, the mutant protein is believed to assume a thermodynamically less stable folded structure, thereby losing any resemblance to wild-type p53, with concomitant abrogation of p53-mediated activities such as transciptional activation of wild-type/?53-responsive genes. This phenomenon could be exploited therapeutically if molecules were designed which reverted the structural integrity of such mutants at the higher non-permissive temperature to wild type conformation.
Restoration of the transciptional activation function to mutant p53 may also be accomplished through exposure to certain anti-p53 monoclonal antibodies such as PAb421 or synthetic basic peptides derived from the C-terminal domain of p53 [101, 102] . Such agents are believed to act by alleviating the constitutive repression by the C-terminus on sequence-specific DNA binding activity. Both mutant and wild-type p53 can be activated by these mechanisms, with the latter form being by far the easiest to vitalise. This is the central crux in deciding whether to utilise p53-activating agents for cancer therapy. Inappropriate activation of wild-type p53 in normal cells may cause unwanted growth arrest or cell death. One argument against this problematic scenario is that the high level of mutant p53 protein commonly found in tumour cells may allow dosing of the activating agent such that wild-type p53 is unaffected. More generally, delivery of p53-activating agents to tumour cells will probably be limited by the size of the macromolecules involved. Improved drugs could be designed with this concept in mind, namely peptide or antibody-loop mimics, which recapitulate the effect of the currently known p53-activating agents.
The antibiotic geldanamycin has been shown to mediate selective destabilsation of several p53 mutants, as indicated by reduction in both the steady-state level and half-life of these mutant proteins with no apparent effects on the wild-type p53 protein [103] . Additionally, geldanamycin treatment appears to alter the conformation of mutant p53 such that mutant-specific antibody epitopes become shielded and partial restoration of sequence-specific DNA binding activity occurs, although this latter effect is controversial [104] . It is thought that this antibiotic binds to certain members of the heatshock protein family, consequently disrupting the stabilising force which these proteins exert upon mutant p53. Opinion is divided, however, as to whether geldanamycin prevents or stimulates nuclear translocation of the mutant p53 protein [104, 105] . Whatever the exact mechanism of action by which geldanamycin destabilises (re-converts?) mutant p53, this drug or more specific analogues may be soon on the way to being tested in clinical situations.
In those tumours which have p53 inactivated through interaction with viral or cellular proteins, alternative strategies might have to be employed which specifically target the interfering protein. One potential avenue of research relies upon the use of ribozyme, antisense or triple DNA helix strategies directed against the gene which is causing the p53 dysfunction [106] . Another 'holy grail' of p53 research has been the elucidation of small molecule inhibitors which block the undesirable interaction between p53 and inactivating proteins, like Mdm2. A crystal structure has been resolved of the Mdm2 protein (N-terminal domain only) complexed with a minimal interacting domain from p53 [107] . The structure of this complex revealed that p53 binds a hydrophobic pocket within Mdm2 that may indeed be accessible to small molecules designed to disrupt the p53/Mdm2 interaction.
Indeed, a synthetic Mdm2-binding mini protein has been recently designed which specifically targets the p53-binding site [108] . An optimised Mdm2-binding peptide, previously isolated from a phage display library, was cloned into the active site loop of the thioredoxin protein -the resulting fusion being called SuperTIP (thioredoxin insert protein). Thioredoxin was chosen as the protein scaffold due to its small size, ease of expression in both eukaryotic and prokaryotic cells, stability and inert quality when the active site loop is removed. The potential of SuperTIP to displace Mdm2 from an inhibitory complex with p53 was shown to be around fifty times greater than a TIP containing the natural Mdm2-binding site within p53. Displacement of Mdm2 from p53 by SuperTIP activated p53-dependent transciption, led to nuclear accumulation of p53 and stimulated cell cycle arrest. One possible point of concern presented by this study is that release of active p53 by inhibitors like SuperTIP was found to be in a reciprocal relationship with the Mdm2 content of the cell. Accordingly, cells with amplified Mdm2 levels may be less responsive than cells with normal expression of Mdm2. Higher affinity inhibitors might overcome such a problem within this cellular context.
Defects in the downstream targets of p53 could be potentially treated with gene replacement therapy by using the appropriate gene involved, or through removal of inactivating proteins if present. These, and other upstream, defects need to be detailed more accurately and any detrimental effect on the p53 pathway clarified before such intervention becomes a reality. Another strategy is to modify the wild-type p53 gene in order to make it more resistant to inactivating factors such as the transdominant negative effects of mutant p53 and Mdm2 overexpression. A couple of investigative groups have already concentrated upon building variants of p53 with a view to this purpose [109, 110] . In one study, the native oligomerisation domain of wild-type p53 was switched with an engineered leucine zipper domain [109] . This modified version of p53 exhibited wild-type p53 function in vitro and in tumour cells. As planned, the engineered leucine zipper domain alleviated transdominant inhibition by a number of p53 mutants. A recent study described the construction of a p53 chimera, called CTS-1, which has both the N-and C-terminal domains substituted with a VP16 activation domain and an optimised leucine zipper domain, respectively [110] . CTS-1 portrayed several interesting properties including enhanced transcriptional activity, resistance to inactivation by either Mdm2 overexpression or oncogenic/755 mutants, reduced sensitivity to E6-induced degradation and enhanced apoptotic activity. In certain cellular contexts, synthetic p53 genes such as these may prove to be more effective in gene replacement therapy than the wild-type p53 gene. As a final note, p73$ was shown to suppress growth and induce apoptosis in E6-overexpressing cells [111] , thus paving a route for this and other newly characterised homologues of the p53 gene in gene therapy applications.
Targeting ofp53 dysfunction
If the problem of restoring p53 function to tumour cells becomes insurmountable, other solutions await. Perhaps the most obvious of all of these is to use anti-tumour agents which work independently of the p53 pathway. An even more attractive approach would be to utilise drugs which act preferentially in p53 defective cells. A comprehensive analysis of 60 tumour cell lines (from the National Cancer Institute anticancer drug screen) showed that most of the currently used chemotherapeutic agents were generally less effective in cells which contained a defective p53 pathway [112] . The types of agents which exhibited this relationship include DNA crosslinkers, anti-metabolites and topoisomerase inhibitors. However, one group of drugs which appeared to work independently of p53 status were the anti-mitotics, for example taxol and vincristine. While the majority of other investigations carried out so far have also shown that the anti-tumour action of taxol is not dependent upon p53 status [113] [114] [115] [116] , some groups have demonstrated either increased or decreased sensitivity to taxol in certain cellular contexts [62, 117] . Care must be taken when classifying chemotherapeutic agents for use in the treatment of p53 defective cells, the crucial factor to be clarified being in which cell types is differential specificity determined. Identification of these agents will probably come from two directions: (1) re-testing of old clinically useful drugs in different contexts or combinations (2) serendipitous isolation or knowledge-based design of new drugs [118] . The overall key to success will be the creation of clear p53-relevant drug screens based in both tumour cell line and animal models.
In certain situations, it may be useful to specifically ablate p53 expression. Most notably, restoration of p53 function by gene replacement therapy with wild-type p53 may be aided by simultaneous inhibition of mutant p53, thus ablating potential dominant negative effects. Also, if 'gain of function' effects by mutant p53 are truly relevant to the tumourigenic process, then reduction of mutant p53 expression should mediate some degree of reversion of the oncogenic phenotype. Finally, in tumour cells which contain both wild-type and mutant p53 protein, specific removal of mutant p53 may be sufficient to restore the endogenous p53 pathway. Expression of p53 may be targeted in a number of ways: ribozyme, antisense and triple-helix strategies again being the primary examples [106] .
An anti-pJ3 ribozyme, which was designed to cleave p53 pre-mRNA, efficiently reduced the level of endogenous mutantp53 mRNA [119] . Inhibition of mutantp53 expression by the ribozyme was sufficient to cause growth suppression of lung cancer cells. This study further supports the idea that mutant p53 on its own can contribute to the transformed phenotype. Although ribozymes such as this one would also cleave wild-type p53 pre-mRNA, expression from exogenously introduced wild-type p53 cDNA should not be affected. Hence, co-expression vectors incorporating both wildtype p53 and p53 -specific ribozymes might be more efficacious than either agent alone. Considerably more work has been accomplished on the design of effective antisense oligonucleotides (AOs) directed against p53. Indeed, several different AOs have been designed which target a variety of regions within the/755 gene, including exon 10 and the translation initiaton codon [120, 121] .
However, no p53 AOs have as yet been described within the literature which solely target mutant p53.
Upon administration of p53 AOs, striking antiproliferative effects have been observed in several tumour cell types in vitro, included amongst these are leukaemic cells along with ovarian and lung cancer cell lines [121] [122] [123] [124] . However, concern has been expressed that the antiproliferative effect of some/755 AOs may be independent of any actual reduction \np53 expression [125] . Two phase I trials have been reported which assess the potential use of p53 AOs for either in vivo systemic therapy of haematological malignancies or ex vivo purging of bone marrow [122, 124] . In both of these cases, the investigators sought to utilise administration ofp53 AOs for specific elimination of leukaemic cells as opposed to normal haematopoietic progenitors. Leukaemic cells in, or derived from, patients suffering from either acute myelogonous leukaemia or myelodysplastic syndrome were the primary targets in these, and previous pre-clinical, studies [120] .
While p53 mutations are infrequently found in haematological malignancies such as these, increased levels of wild-type p53 protein, in comparison to normal cells, are often present [126] . Thus, it may not always be necessary to exclusively inhibit mutant p53 expression, as in certain cellular contexts, including those indicated above, reduction of wild-type p53 mRNA by AOs may also lead to cytotoxic effects. The first phase I trial revealed that a p53 phosphorothioate AO could be administered systemically with minimal degradation, as indicated by intact recovery of the AO in the urine of treated patients [122] . While no complete clinical responses were seen, it was reported that relatively high doses of this p53 AO could be given without evidence of significant toxicity. In another phase I trial, the same/>55 AO was used for the ex vivo removal of leukaemic cells from autologous bone marrow subsequently used for transplantation [124] . Although the efficiency of purging could not be determined in this trial, patient infusion of bone marrow treated with the p53 AO was shown to be safe at doses previously shown in earlier in vitro studies to be sufficient for selective cytotoxicity against leukaemic cells [120] .
Approximately 25% of all cancer patients mount a humoral immune response against p53 protein [56] . This humoral response against p53 in cancer patients may be useful not only for diagnosis, but may also have direct implications for therapy [127, 128] . The main hope of p53-based immunotherapy revolves around triggering a cytotoxic T-lymphocyte (CTL) response against tumour cells expressing mutant p53. One scenario is that mutant p53 -specific epitopes presented on the cell surface could serve as selective targets. While CTLs demonstrate the ability to differentiate between mutant and wild-type p53 proteins [129] , there appears to be an immunoselection process against those tumours which express immunopositive mutant p53-specific epitopes [130] . Alternatively, since overexpression of mutant p53 is a frequently occuring phenomenon in tumour cells, it follows on that there is a greater potential for enhanced presentation of peptides derived from non-mutated regions of the mutated p53 molecule. The advantage of triggering a CTL response against wild-type p53-specific epitopes is clear when one considers the vast number of possible missense mutation sites within p53. Wild-type p53 peptide-based immunotherapy has shown some efficacy with regard to tumour eradication in mouse models [131, 132] . However, one study has indicated that in certain cases p53-specific immunotherapy may be successful only if the mutated protein is taken into consideration [133] . In another strategy to generate p53-specific cancer vaccines, wild-type and mutant p53 were cloned into canarypox virus expression vectors and used to protect mice against mutant p53 tumour cell challenge [134] . Both forms of p53 proved to be equally effective as regards protection against tumour formation through the induction of an immune response. Finally, a recent study has reported the potential use of antibodies to p53 as immunogens for activating resistance to tumours containing mutant p53 [135] .
Another interesting approach to p53-based cancer therapy has been developed which also seeks to exploit the presence of elevated mutant p53 protein in tumour cells [136] . The principle of this strategy relies upon the formation of an intracellular protein complex between an exogenously introduced hybrid protein (in this case, the DNA binding domain of Gal4 fused to p53 binding domain of SV40 large T antigen) and endogenous p53 protein. Formation of this complex permits the transcriptional activation of a 'weapon' gene, whose protein product can convert an inert substrate into a cytotoxic agent. In the pilot study, the weapon gene encoded for purine nucleoside phosphorylase, an enzyme which catalyzes the conversion of the non-toxic prodrug 6-methylpurine deoxyriboside to the toxic 6-methylpurine, thus causing cell death. The above system is not inherently specific for mutant p53 as high levels of wild-type p53 protein would mediate the same effect. But, as mentioned previously, most normal cells only express a very low level of p53 protein, which should not result in any significant activation of transgene expression. One distinct advantage to this strategy is the possibility of a bystander effect generated by the diffusion of toxic product to surrounding tumour cells. Further improvement to this system may be accomplished by the engineering of a mutant p53-specific binding domain into the 'trigger' protein.
A novel therapeutic strategy directed against tumours with defective p53 function has been developed [137] . A human adenovirus, ONYX-015, which has a deletion in the Elb 55kDa protein has shown dramatic activity in preclinical models of cancer [138] and is now undergoing clinical trial. The Elb 55kDa protein can bind to and inactivate p53 and it has been demonstrated that this interaction is essential for allowing viral replication to proceed [139] . Consequently, it was proposed that the mutant adenovirus would be able to replicate in, and ultimately lyse, cells with dysfunctional p53 while retaining an inability to progress within normal cells.
The most attractive feature of this approach is the potential for virus spread which may permit improvement upon the low efficiency of gene transfer currently observed in gene therapy protocols for cancer [68] . Using cultured cells and tumour-bearing mice, an initial study showed that ONYX-015 can replicate in and lyse tumour cells with defective p53, whereas cytopathic effects with the mutant adenovirus were reduced approximately 100 fold in cells with wild-type p53 function [68] . However, a number of subsequent studies have questioned the selective action of ONYX-015 and have failed to show an association between ability of Elb-defective adenoviruses to replicate and p53 status [140, 141] . It has been claimed that ONYX-015 can replicate in cells with wild type p53 and that cells lacking p53 function are resistant to adenovirus induced cell death [142] . The reason for these apparent conflicting results on the specificity of the virus remains unclear [143] and further studies are necessary to help unravel the mechanisms of ONYX-015 action. Nevertheless, these first generation smart viruses show considerable preclinical efficacy and should be further studied and improved.
Onyx-015 has demonstrated considerable efficacy against transplanted tumours in nude mice, following either direct intratumoural or systemic delivery (138) . Furthermore, combination of ONYX-015 administration and chemotherapy (cisplatin or 5-fluorouracil) proved more efficacious than either agent alone. Intriguingly, ONYX-015 efficiently lysed a number of tumour cell lines which had acquired resistance to chemotherapeutic agents such as cisplatin and doxorubicin, thus raising the possibility that the mutant adenovirus may regress tumours where conventional therapy has failed. At the present moment, several phase I and II trials are examining the effect of intratumoural, intraperitoneal and regional tissue administration of ONYX-015 into cancer patients with ovarian and head-and-neck tumours among other types. A passible indication of future treatment regimens incorporating this type of therapy was revealed in a recent report which used a three-pronged approach involving viral, double suicide gene, and radiotherapy [144] . In this study, an attenuated virus similar in design to ONYX-015 was constructed but with two added genes typically used in suicide gene therapy applications, cytosine deaminase and HSV thymidine kinase. These suicide gene systems, while aiding in the anti-tumour action of the virus, may also be used to provide an extra layer of control against over-zealous viral spread and specificity to tumour cells.
Conclusions
Tremendous progress has been made in understanding the various functions of p53. The important role that p53 plays in responding to stresses such as DNA damage clearly indicates a central biological pathway within the cell. While all of the upstream and downstream components of the p53 pathway have yet to be deciphered and wired together, a large number of investigators have sought to exploit known aspects of p53 research in the design of p53-orientated cancer therapies. The strategies which have been developed differ greatly between themselves both in the mode of action and the degree of success currently seen in experimental models. Rapid progress is expected to be made regarding the identification of conventional pharmaceutical agents which either work in a p53-independent manner or act preferentially in p53 defective cells. Gene replacement therapy with wild-type p53 also holds considerable potential for obtaining clinically relevant results quickly. The other forms of cancer therapies based around p53 are much further behind in the developmental process (with the exception of ONYX-015), but may prove to more efficacious in the long run, especially in terms of specificity. As with many other fields, the innovation of successful p53-oriented cancer therapies is only limited by our understanding of p53 biology and the creative use of such knowledge. The future of p53 in the clinic is set to be an interesting one.
